Search

Your search keyword '"Visseren, Frank L J"' showing total 1,071 results
Start Over Author "Visseren, Frank L J"
1,071 results on '"Visseren, Frank L J"'

7. Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study

Author

Ray, Kausik K, primary, Aguiar, Carlos, additional, Arca, Marcello, additional, Connolly, Derek L, additional, Eriksson, Mats, additional, Ferrières, Jean, additional, Laufs, Ulrich, additional, Mostaza, Jose M, additional, Nanchen, David, additional, Bardet, Aurélie, additional, Lamparter, Mathias, additional, Chhabra, Richa, additional, Soronen, Jarkko, additional, Rietzschel, Ernst, additional, Strandberg, Timo, additional, Toplak, Hermann, additional, Visseren, Frank L J, additional, and Catapano, Alberico L, additional

Published
2024
Full Text
View/download PDF

8. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Author

Agarwal, Abhay, Ballantyne, Christie, Baum, Seth, Bergeron, Jean, Bruckert, Eric, Burdick, Richard, Castro-Cabezas, Manuel, Cervi, Mark, Corder, Clinton, DuFour, Robert, Farrington, Cecil Murray, Francis, Gordon, Galitz, Lawrence, Hamstead, Steven, Hemphill, Linda, Huffman, Cynthia, Issa, Basil, Julius, Ulrich, Kane, John, Krempf, Michel, Martin, Steven, Powell, James, Shultzaberger, Richard, Thompson, Craig, Thompson-Hargrave, Letitia, Toth, Peter, Turner, Traci, Valero, Rene, Verges, Bruno, Visseren, Frank L J, Vyas, Pankaj, Yataco, Alberto, Gouni-Berthold, Ioanna, Alexander, Veronica J, Yang, Qingqing, Hurh, Eunju, Steinhagen-Thiessen, Elisabeth, Moriarty, Patrick M, Hughes, Stephen G, Gaudet, Daniel, Hegele, Robert A, O'Dea, Louis St L, Stroes, Erik S G, Tsimikas, Sotirios, and Witztum, Joseph L

Published
2021
Full Text
View/download PDF

14. Sex differences in modifiable risk factors for stroke incidence and recurrence: the UCC-SMART study

Author

Cardiovasculaire Epi Team 7a, Cardiovasculaire Epidemiologie, Neurologen, Global Health, Circulatory Health, Interne Geneeskunde Vasculaire, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovascular Health, Brain, Rissanen, Ina, Basten, Maartje, Exalto, Lieza G, Peters, Sanne A E, Visseren, Frank L J, Geerlings, Mirjam I, UCC-SMART Study Group, Cardiovasculaire Epi Team 7a, Cardiovasculaire Epidemiologie, Neurologen, Global Health, Circulatory Health, Interne Geneeskunde Vasculaire, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovascular Health, Brain, Rissanen, Ina, Basten, Maartje, Exalto, Lieza G, Peters, Sanne A E, Visseren, Frank L J, Geerlings, Mirjam I, and UCC-SMART Study Group

Published
2024

15. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model

Author

Interne Geneeskunde Vasculaire, Circulatory Health, MS Interne Geneeskunde, Global Health, Helmink, Marga A G, Hageman, Steven H J, Eliasson, Björn, Sattar, Naveed, Visseren, Frank L J, Dorresteijn, Jannick A N, Harris, Katie, Peters, Sanne A E, Woodward, Mark, Szentkúti, Péter, Højlund, Kurt, Henriksen, Jan Erik, Sørensen, Henrik Toft, Serné, Erik H, van Sloten, Thomas T, Thomsen, Reimar W, Westerink, Jan, Interne Geneeskunde Vasculaire, Circulatory Health, MS Interne Geneeskunde, Global Health, Helmink, Marga A G, Hageman, Steven H J, Eliasson, Björn, Sattar, Naveed, Visseren, Frank L J, Dorresteijn, Jannick A N, Harris, Katie, Peters, Sanne A E, Woodward, Mark, Szentkúti, Péter, Højlund, Kurt, Henriksen, Jan Erik, Sørensen, Henrik Toft, Serné, Erik H, van Sloten, Thomas T, Thomsen, Reimar W, and Westerink, Jan

Published
2024

16. Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

Author

Interne Geneeskunde Vasculaire, Circulatory Health, MS Interne Geneeskunde, Holtrop, Joris, Bhatt, Deepak L, Ray, Kausik K, Mach, François, Smulders, Yvo M, Carballo, David, Steg, Philippe Gabriel, Visseren, Frank L J, Dorresteijn, Jannick A N, Interne Geneeskunde Vasculaire, Circulatory Health, MS Interne Geneeskunde, Holtrop, Joris, Bhatt, Deepak L, Ray, Kausik K, Mach, François, Smulders, Yvo M, Carballo, David, Steg, Philippe Gabriel, Visseren, Frank L J, and Dorresteijn, Jannick A N

Published
2024

17. Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease

Author

Unit Opleiding Aios, Interne Geneeskunde Vasculaire, Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Team Medisch, MS Interne Geneeskunde, Castelijns, Maria C, Hageman, Steven H J, Teraa, Martin, van der Meer, Manon G, Westerink, Jan, Ten Berg, Jurrien, Visseren, Frank L J, Unit Opleiding Aios, Interne Geneeskunde Vasculaire, Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Team Medisch, MS Interne Geneeskunde, Castelijns, Maria C, Hageman, Steven H J, Teraa, Martin, van der Meer, Manon G, Westerink, Jan, Ten Berg, Jurrien, and Visseren, Frank L J

Published
2024

18. Cost-effectiveness of Mediterranean diet and physical activity in secondary cardiovascular disease prevention: results from the UCC-SMART cohort study

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Cardiometabolic Health, JC onderzoeksprogramma Cardiovascular Health, Team Medisch, Zorgeenheid Vaatchirurgie Medisch, Neurologen, Brain, Unit Opleiding Aios, Bonekamp, Nadia E, Visseren, Frank L J, van der Schouw, Yvonne T, van der Meer, Manon G, Teraa, Martin, Ruigrok, Ynte, Geleijnse, Johanna M, Koopal, Charlotte, UCC-SMART Study Group, Interne Geneeskunde Vasculaire, Circulatory Health, Cardiometabolic Health, JC onderzoeksprogramma Cardiovascular Health, Team Medisch, Zorgeenheid Vaatchirurgie Medisch, Neurologen, Brain, Unit Opleiding Aios, Bonekamp, Nadia E, Visseren, Frank L J, van der Schouw, Yvonne T, van der Meer, Manon G, Teraa, Martin, Ruigrok, Ynte, Geleijnse, Johanna M, Koopal, Charlotte, and UCC-SMART Study Group

Published
2024

19. Plasma lipids in Pseudoxanthoma Elasticum (PXE) patients: A comparative study with population-based reference values and Non-PXE controls

Author

Interne Geneeskunde Vasculaire, Circulatory Health, MS Radiologie, Researchgr. Systems Radiology, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, MS Interne Geneeskunde, Harmsen, Iris M, Visseren, Frank L J, Kok, Madeleine, de Jong, Pim A, Spiering, Wilko, Interne Geneeskunde Vasculaire, Circulatory Health, MS Radiologie, Researchgr. Systems Radiology, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, MS Interne Geneeskunde, Harmsen, Iris M, Visseren, Frank L J, Kok, Madeleine, de Jong, Pim A, and Spiering, Wilko

Published
2024

20. Long-term lifestyle change and risk of mortality and type 2 diabetes in patients with cardiovascular disease

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Team Medisch, MS Interne Geneeskunde, Neurologen, Brain, Zorgeenheid Vaatchirurgie Medisch, Regenerative Medicine and Stem Cells, Unit Opleiding Aios, Bonekamp, Nadia E, Visseren, Frank L J, Cramer, Maarten J, Dorresteijn, Jannick A N, van der Meer, Manon G, Ruigrok, Y M, van Sloten, Thomas T, Teraa, Martin, Geleijnse, Johanna M, Koopal, Charlotte, Interne Geneeskunde Vasculaire, Circulatory Health, Team Medisch, MS Interne Geneeskunde, Neurologen, Brain, Zorgeenheid Vaatchirurgie Medisch, Regenerative Medicine and Stem Cells, Unit Opleiding Aios, Bonekamp, Nadia E, Visseren, Frank L J, Cramer, Maarten J, Dorresteijn, Jannick A N, van der Meer, Manon G, Ruigrok, Y M, van Sloten, Thomas T, Teraa, Martin, Geleijnse, Johanna M, and Koopal, Charlotte

Published
2024

21. Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

Author

Holtrop, Joris, primary, Bhatt, Deepak L, additional, Ray, Kausik K, additional, Mach, François, additional, Smulders, Yvo M, additional, Carballo, David, additional, Steg, Philippe Gabriel, additional, Visseren, Frank L J, additional, and Dorresteijn, Jannick A N, additional

Published
2024
Full Text
View/download PDF

23. Cyclical Etidronate Reduces the Progression of Arterial Calcifications in Patients with Pseudoxanthoma Elasticum: A 6-Year Prospective Observational Study.

Author

Harmsen, Iris M., van den Beukel, Tim, Kok, Madeleine, Visseren, Frank L. J., de Jong, Pim A., Papapoulos, Socrates E., and Spiering, Wilko

Subjects
ARTERIAL calcification, GENETIC disorders, COMPUTED tomography, CALCIFICATION, GENETIC mutation
Abstract

Background: Pseudoxanthoma elasticum (PXE), a rare genetic disorder presenting with slowly progressing calcification of various tissues, including the arteries, is caused by mutations in the ABCC6 gene that lead to the reduction of pyrophosphate, a natural inhibitor of calcification. We showed that, compared to a placebo, the cyclical administration of etidronate, a stable pyrophosphate analog, significantly reduced arterial calcification assessed by low-dose CT scans after one year. The aim of the present prospective, single center, observational cohort study was the assessment of the efficacy and safety of cyclical etidronate in patients treated for periods longer than one year. Methods: Seventy-three patients were followed for a median of 3.6 years without etidronate and 2.8 years with etidronate, and each patient served as their own control. Results: The median absolute yearly progression of total calcification volume during the period with etidronate (388 [83–838] µL) was significantly lower than that without etidronate (761 [362–1415] µL; p < 0.001). The rates of the relative progression of arterial calcification were 11.7% (95% CI: 9.6–13.9) without etidronate compared to 5.3% (95% CI: 3.7–7.0) with etidronate, after adjustment for confounders. Conclusions: The cyclical administration of etidronate for nearly 3 years significantly reduced the progression rate of arterial calcification in patients with PXE with pre-existing calcifications without any serious adverse effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model.

Author

Helmink, Marga A. G., Hageman, Steven H. J., Eliasson, Björn, Sattar, Naveed, Visseren, Frank L. J., Dorresteijn, Jannick A. N., Harris, Katie, Peters, Sanne A. E., Woodward, Mark, Szentkúti, Péter, Højlund, Kurt, Henriksen, Jan Erik, Sørensen, Henrik Toft, Serné, Erik H., van Sloten, Thomas T., Thomsen, Reimar W., and Westerink, Jan

Subjects
TYPE 1 diabetes, PROPORTIONAL hazards models, CARDIOVASCULAR diseases risk factors, SYSTOLIC blood pressure, GLOMERULAR filtration rate, BODY mass index
Abstract

Aims: To develop and externally validate the LIFE‐T1D model for the estimation of lifetime and 10‐year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. Materials and Methods: A sex‐specific competing risk‐adjusted Cox proportional hazards model was derived in individuals with type 1 diabetes without prior CVD from the Swedish National Diabetes Register (NDR), using age as the time axis. Predictors included age at diabetes onset, smoking status, body mass index, systolic blood pressure, glycated haemoglobin level, estimated glomerular filtration rate, non‐high‐density lipoprotein cholesterol, albuminuria and retinopathy. The model was externally validated in the Danish Funen Diabetes Database (FDDB) and the UK Biobank. Results: During a median follow‐up of 11.8 years (interquartile interval 6.1–17.1 years), 4608 CVD events and 1316 non‐CVD deaths were observed in the NDR (n = 39 756). The internal validation c‐statistic was 0.85 (95% confidence interval [CI] 0.84–0.85) and the external validation c‐statistics were 0.77 (95% CI 0.74–0.81) for the FDDB (n = 2709) and 0.73 (95% CI 0.70–0.77) for the UK Biobank (n = 1022). Predicted risks were consistent with the observed incidence in the derivation and both validation cohorts. Conclusions: The LIFE‐T1D model can estimate lifetime risk of CVD and CVD‐free life expectancy in individuals with type 1 diabetes without previous CVD. This model can facilitate individualized CVD prevention among individuals with type 1 diabetes. Validation in additional cohorts will improve future clinical implementation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Validating the SMART2 Score in a Racially Diverse High‐Risk Nationwide Cohort of Patients Receiving Coronary Artery Bypass Grafting

Author

Deo, Salil V., primary, Althouse, Andrew, additional, Al‐Kindi, Sadeer, additional, McAllister, David A., additional, Orkaby, Ariela, additional, Elgudin, Yakov E., additional, Fremes, Stephen, additional, Chu, Danny, additional, Visseren, Frank L. J., additional, Pell, Jill P., additional, and Sattar, Naveed, additional

Published
2023
Full Text
View/download PDF

28. Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment

Author

Seekircher, Lisa, primary, Tschiderer, Lena, additional, Lind, Lars, additional, Safarova, Maya S, additional, Kavousi, Maryam, additional, Ikram, M Arfan, additional, Lonn, Eva, additional, Yusuf, Salim, additional, Grobbee, Diederick E, additional, Kastelein, John J P, additional, Visseren, Frank L J, additional, Walters, Matthew, additional, Dawson, Jesse, additional, Higgins, Peter, additional, Agewall, Stefan, additional, Catapano, Alberico, additional, de Groot, Eric, additional, Espeland, Mark A, additional, Klingenschmid, Gerhard, additional, Magliano, Dianna, additional, Olsen, Michael H, additional, Preiss, David, additional, Sander, Dirk, additional, Skilton, Michael, additional, Zozulińska-Ziółkiewicz, Dorota A, additional, Grooteman, Muriel P C, additional, Blankestijn, Peter J, additional, Kitagawa, Kazuo, additional, Okazaki, Shuhei, additional, Manzi, Maria V, additional, Mancusi, Costantino, additional, Izzo, Raffaele, additional, Desvarieux, Moise, additional, Rundek, Tatjana, additional, Gerstein, Hertzel C, additional, Bots, Michiel L, additional, Sweeting, Michael J, additional, Lorenz, Matthias W, additional, and Willeit, Peter, additional

Published
2023
Full Text
View/download PDF

29. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data

Author

Chalmers, John, Arima, Hisatomi, Perkovic, Vlado, Grams, Morgan E., Sang, Yingying, Schaeffner, Elke, Martus, Peter, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Heine, Gunnar, Seiler, Sarah, Zawada, Adam, Emrich, Insa, Sarnak, Mark, Katz, Ronit, Brenner, Hermann, Schöttker, Ben, Rothenbacher, Dietrich, Saum, Kai-Uwe, Köttgen, Anna, Schneider, Markus, Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R, Black, Corri, Marks, Angharad, Prescott, Gordon, Clark, Laura, Fluck, Nick, Jee, Sun Ha, Mok, Yejin, Chodick, Gabriel, Shalev, Varda, Wetzels, Jack F.M., Blankestijn, Peter J, van Zuilen, Arjan D, Bots, M, Peralta, Carmen, Hiromoto, Jade, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen B, Nadukuru, Rajiv, Kenealy, Timothy, Elley, C Raina, Collins, John F, Drury, Paul L, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, Jassal, Simerjot K, Bergstrom, Jaclyn, Ix, Joachim H, Barrett-Connor, Elizabeth, Kalantar-Zadeh, Kamyar, Carrero, Juan J, Gasparini, Alessandro, Qureshi, Abdul Rashid, Barany, Peter, Algra, Ale, van der Graaf, Yolanda, Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Lannfelt, Lars, Larsson, Anders, Hallan, Stein, Levey, Andrew S, Chen, Jingsha, Kwak, Lucia, Matsushita, Kunihiro, Ballew, Shoshana H, Coresh, Josef, Ärnlöv, Johan, Cirillo, Massimo, Ebert, Natalie, Hiramoto, Jade S, Kimm, Heejin, Shlipak, Michael G, Visseren, Frank L J, Gansevoort, Ron T, Kovesdy, Csaba P, Woodward, Mark, and Kronenberg, Florian

Published
2017
Full Text
View/download PDF

32. Association of body mass index and waist circumference with long-term mortality risk in 10,370 coronary patients and potential modification by lifestyle and health determinants.

Author

Cruijsen, Esther, Bonekamp, Nadia E., Koopal, Charlotte, Winkels, Renate M., Visseren, Frank L. J., and Geleijnse, Johanna M.

Subjects
BODY mass index, WAIST circumference, PHYSICAL activity, CORONARY artery disease, MORTALITY
Abstract

Background and aims: Body adiposity is known to affect mortality risk in patients with coronary artery disease (CAD). We examined associations of body mass index (BMI) and waist circumference (WC) with long term mortality in Dutch CAD patients, and potential and effect modification of these associations by lifestyle and health determinants. Methods: 10,370 CAD patients (mean age ∼65 y; 20% female; >80% on cardiovascular drugs) from the prospective Alpha Omega Cohort and Utrecht Cardiovascular Cohort–Secondary Manifestations of ARTerial disease study were included. Cox models were used to estimate categorical and continuous associations (using restricted cubic splines) of measured BMI and WC with all-cause and cardiovascular mortality risk, adjusting for age, sex, smoking, alcohol, physical activity and educational level. Analyses were repeated in subgroups of lifestyle factors (smoking, physical activity, diet quality), education and health determinants (diabetes, self-rated health). Results: During ∼10 years of follow-up (91,947 person-years), 3,553 deaths occurred, including 1,620 from cardiovascular disease. U-shaped relationships were found for BMI and mortality risk, with the lowest risk for overweight patients (BMI ∼27 kg/m2). For obesity (BMI ≥30), the HR for all-cause mortality was 1.31 (95% CI: 1.11, 1.41) in male patients and 1.10 (95% CI: 0.92, 1.30) in female patients, compared to BMI 25–30 kg/m2. WC was also non-linearly associated with mortality, and HRs were 1.18 (95%CI:1.06, 1.30) in males and 1.31 (95%CI:1.05, 1.64) in females for the highest vs. middle category of WC. Results for cardiovascular mortality were mostly in line with the results for all-cause mortality. U-shaped associations were found in most subgroups, associations were moderately modified by physical activity, smoking and educational level. Conclusions: CAD patients with obesity and a large WC were at increased risk of long-term CVD and all-cause mortality, while mildly overweight patients had the lowest risk. These associations were consistent across subgroups of patients with different lifestyles and health status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

Author

Hageman, Steven H J, primary, Petitjean, Carmen, additional, Pennells, Lisa, additional, Kaptoge, Stephen, additional, Pajouheshnia, Romin, additional, Tillmann, Taavi, additional, Blaha, Michael J, additional, McClelland, Robyn L, additional, Matsushita, Kunihiro, additional, Nambi, Vijay, additional, Klungel, Olaf H, additional, Souverein, Patrick C, additional, van der Schouw, Yvonne T, additional, Verschuren, W M Monique, additional, Lehmann, Nils, additional, Erbel, Raimund, additional, Jöckel, Karl-Heinz, additional, Di Angelantonio, Emanuele, additional, Visseren, Frank L J, additional, and Dorresteijn, Jannick A N, additional

Published
2023
Full Text
View/download PDF

36. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes : An Individual-Participant Data Meta-Analysis.

Author

Grams, Morgan E, Coresh, Josef, Matsushita, Kunihiro, Ballew, Shoshana H, Sang, Yingying, Surapaneni, Aditya, Alencar de Pinho, Natalia, Anderson, Amanda, Appel, Lawrence J, Ärnlöv, Johan, Azizi, Fereidoun, Bansal, Nisha, Bell, Samira, Bilo, Henk J G, Brunskill, Nigel J, Carrero, Juan J, Chadban, Steve, Chalmers, John, Chen, Jing, Ciemins, Elizabeth, Cirillo, Massimo, Ebert, Natalie, Evans, Marie, Ferreiro, Alejandro, Fu, Edouard L, Larsson, Anders, Gutierrez, Orlando M, Herrington, William G, Hwang, Shih-Jen, Inker, Lesley A, Iseki, Kunitoshi, Jafar, Tazeen, Jassal, Simerjot K, Jha, Vivekanand, Kadota, Aya, Katz, Ronit, Köttgen, Anna, Konta, Tsuneo, Kronenberg, Florian, Lee, Brian J, Lees, Jennifer, Levin, Adeera, Looker, Helen C, Major, Rupert, Melzer Cohen, Cheli, Mieno, Makiko, Miyazaki, Mariko, Moranne, Olivier, Muraki, Isao, Naimark, David, Nitsch, Dorothea, Oh, Wonsuk, Pena, Michelle, Purnell, Tanjala S, Sabanayagam, Charumathi, Satoh, Michihiro, Sawhney, Simon, Schaeffner, Elke, Schöttker, Ben, Shen, Jenny I, Shlipak, Michael G, Sinha, Smeeta, Stengel, Benedicte, Sumida, Keiichi, Tonelli, Marcello, Valdivielso, Jose M, van Zuilen, Arjan D, Visseren, Frank L J, Wang, Angela Yee-Moon, Wen, Chi-Pang, Wheeler, David C, Yatsuya, Hiroshi, Yamagata, Kunihiro, Yang, Jae Won, Young, Ann, Zhang, Haitao, Zhang, Luxia, Levey, Andrew S, Gansevoort, Ron T, Grams, Morgan E, Coresh, Josef, Matsushita, Kunihiro, Ballew, Shoshana H, Sang, Yingying, Surapaneni, Aditya, Alencar de Pinho, Natalia, Anderson, Amanda, Appel, Lawrence J, Ärnlöv, Johan, Azizi, Fereidoun, Bansal, Nisha, Bell, Samira, Bilo, Henk J G, Brunskill, Nigel J, Carrero, Juan J, Chadban, Steve, Chalmers, John, Chen, Jing, Ciemins, Elizabeth, Cirillo, Massimo, Ebert, Natalie, Evans, Marie, Ferreiro, Alejandro, Fu, Edouard L, Larsson, Anders, Gutierrez, Orlando M, Herrington, William G, Hwang, Shih-Jen, Inker, Lesley A, Iseki, Kunitoshi, Jafar, Tazeen, Jassal, Simerjot K, Jha, Vivekanand, Kadota, Aya, Katz, Ronit, Köttgen, Anna, Konta, Tsuneo, Kronenberg, Florian, Lee, Brian J, Lees, Jennifer, Levin, Adeera, Looker, Helen C, Major, Rupert, Melzer Cohen, Cheli, Mieno, Makiko, Miyazaki, Mariko, Moranne, Olivier, Muraki, Isao, Naimark, David, Nitsch, Dorothea, Oh, Wonsuk, Pena, Michelle, Purnell, Tanjala S, Sabanayagam, Charumathi, Satoh, Michihiro, Sawhney, Simon, Schaeffner, Elke, Schöttker, Ben, Shen, Jenny I, Shlipak, Michael G, Sinha, Smeeta, Stengel, Benedicte, Sumida, Keiichi, Tonelli, Marcello, Valdivielso, Jose M, van Zuilen, Arjan D, Visseren, Frank L J, Wang, Angela Yee-Moon, Wen, Chi-Pang, Wheeler, David C, Yatsuya, Hiroshi, Yamagata, Kunihiro, Yang, Jae Won, Young, Ann, Zhang, Haitao, Zhang, Luxia, Levey, Andrew S, and Gansevoort, Ron T

Abstract

IMPORTANCE: Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US. OBJECTIVE: To evaluate associations of lower eGFR based on creatinine alone, lower eGFR based on creatinine combined with cystatin C, and more severe albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes. DESIGN, SETTING, AND PARTICIPANTS: Individual-participant data meta-analysis of 27 503 140 individuals from 114 global cohorts (eGFR based on creatinine alone) and 720 736 individuals from 20 cohorts (eGFR based on creatinine and cystatin C) and 9 067 753 individuals from 114 cohorts (albuminuria) from 1980 to 2021. EXPOSURES: The Chronic Kidney Disease Epidemiology Collaboration 2021 equations for eGFR based on creatinine alone and eGFR based on creatinine and cystatin C; and albuminuria estimated as urine albumin to creatinine ratio (UACR). MAIN OUTCOMES AND MEASURES: The risk of kidney failure requiring replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The analyses were performed within each cohort and summarized with random-effects meta-analyses. RESULTS: Within the population using eGFR based on creatinine alone (mean age, 54 years [SD, 17 years]; 51% were women; mean follow-up time, 4.8 years [SD, 3.3 years]), the mean eGFR was 90 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 11 mg/g (IQR, 8-16 mg/g). Within the population using eGFR based on creatinine and cystatin C (mean age, 59 years [SD, 12 years]; 53% were women; mean follow-up time, 10.8 years [SD, 4.1 years]), the mean eGFR was 88 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 9 mg/g (IQR, 6-18 mg/g). Lower eGFR (whether based on creatinine alone or based on creatinine and cystatin C) and higher UACR were each significantly associ

Published
2023
Full Text
View/download PDF

37. Comparison of the European and U.S. guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Delabays, Benoît, de La Harpe, Roxane, Vollenweider, Peter, Fournier, Stephane, Müller, Olivier, Strambo, Davide, Graham, Ian, Visseren, Frank L J, Nanchen, David, Marques-Vidal, Pedro, Vaucher, Julien, Interne Geneeskunde Vasculaire, Circulatory Health, Delabays, Benoît, de La Harpe, Roxane, Vollenweider, Peter, Fournier, Stephane, Müller, Olivier, Strambo, Davide, Graham, Ian, Visseren, Frank L J, Nanchen, David, Marques-Vidal, Pedro, and Vaucher, Julien

Published
2023

38. Validating the SMART2 Score in a Racially Diverse High-Risk Nationwide Cohort of Patients Receiving Coronary Artery Bypass Grafting

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Deo, Salil V, Althouse, Andrew, Al-Kindi, Sadeer, McAllister, David A, Orkaby, Ariela, Elgudin, Yakov E, Fremes, Stephen, Chu, Danny, Visseren, Frank L J, Pell, Jill P, Sattar, Naveed, Interne Geneeskunde Vasculaire, Circulatory Health, Deo, Salil V, Althouse, Andrew, Al-Kindi, Sadeer, McAllister, David A, Orkaby, Ariela, Elgudin, Yakov E, Fremes, Stephen, Chu, Danny, Visseren, Frank L J, Pell, Jill P, and Sattar, Naveed

Published
2023

39. Temporal Trends and Determinants of Stroke Risk in Patients With Medically Treated Asymptomatic Carotid Stenosis

Author

Opleiding Neurologie, Zorgeenheid Vaatchirurgie Medisch, Interne Geneeskunde Vasculaire, Circulatory Health, Neurologen, Brain, Cardiovasculaire Epi Team 5, Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 7a, Regenerative Medicine and Stem Cells, Poorthuis, Michiel H F, Solomon, Yoel, Herings, Reinier A R, Visseren, Frank L J, Kappelle, L Jaap, Bots, Michiel L, Rissanen, Ina, de Borst, Gert J, Opleiding Neurologie, Zorgeenheid Vaatchirurgie Medisch, Interne Geneeskunde Vasculaire, Circulatory Health, Neurologen, Brain, Cardiovasculaire Epi Team 5, Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 7a, Regenerative Medicine and Stem Cells, Poorthuis, Michiel H F, Solomon, Yoel, Herings, Reinier A R, Visseren, Frank L J, Kappelle, L Jaap, Bots, Michiel L, Rissanen, Ina, and de Borst, Gert J

Published
2023

40. Physical exercise volume, type, and intensity and risk of all-cause mortality and cardiovascular events in patients with cardiovascular disease: a mediation analysis

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Epi Kanker, Cancer, JC onderzoeksprogramma Cancer, MS Interne Geneeskunde, Team Medisch, Neurologen, Brain, Zorgeenheid Vaatchirurgie Medisch, Regenerative Medicine and Stem Cells, Unit Opleiding Aios, Bonekamp, Nadia E, May, Anne M, Halle, Martin, Dorresteijn, Jannick A N, van der Meer, Manon G, Ruigrok, Ynte M, de Borst, Gert J, Geleijnse, Johanna M, Visseren, Frank L J, Koopal, Charlotte, Interne Geneeskunde Vasculaire, Circulatory Health, Epi Kanker, Cancer, JC onderzoeksprogramma Cancer, MS Interne Geneeskunde, Team Medisch, Neurologen, Brain, Zorgeenheid Vaatchirurgie Medisch, Regenerative Medicine and Stem Cells, Unit Opleiding Aios, Bonekamp, Nadia E, May, Anne M, Halle, Martin, Dorresteijn, Jannick A N, van der Meer, Manon G, Ruigrok, Ynte M, de Borst, Gert J, Geleijnse, Johanna M, Visseren, Frank L J, and Koopal, Charlotte

Published
2023

41. The relevance of competing risk adjustment in cardiovascular risk prediction models for clinical practice

Author

Interne Geneeskunde Vasculaire, MS Interne Geneeskunde, Circulatory Health, Epi Methoden Team 3, Infection & Immunity, Cardiovasculaire Epi Team 5, Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Hageman, Steven H J, Dorresteijn, Jannick A N, Pennells, Lisa, van Smeden, Maarten, Bots, Michiel L, Di Angelantonio, Emanuele, Visseren, Frank L J, Interne Geneeskunde Vasculaire, MS Interne Geneeskunde, Circulatory Health, Epi Methoden Team 3, Infection & Immunity, Cardiovasculaire Epi Team 5, Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Hageman, Steven H J, Dorresteijn, Jannick A N, Pennells, Lisa, van Smeden, Maarten, Bots, Michiel L, Di Angelantonio, Emanuele, and Visseren, Frank L J

Published
2023

42. Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia

Author

Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Circulatory Health, Heidemann, Britt E, Koopal, Charlotte, Roeters van Lennep, Jeanine E, Stroes, Erik S G, Riksen, Niels P, Mulder, Monique T, van der Zee, Leonie C van Vark, Blackhurst, Dee M, Marais, A David, Visseren, Frank L J, Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Circulatory Health, Heidemann, Britt E, Koopal, Charlotte, Roeters van Lennep, Jeanine E, Stroes, Erik S G, Riksen, Niels P, Mulder, Monique T, van der Zee, Leonie C van Vark, Blackhurst, Dee M, Marais, A David, and Visseren, Frank L J

Published
2023

43. Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2)

Author

Interne Geneeskunde Vasculaire, Circulatory Health, MS Interne Geneeskunde, Østergaard, Helena Bleken, Hageman, Steven H J, Read, Stephanie H, Taylor, Owen, Pennells, Lisa, Kaptoge, Stephen, Petitjean, Carmen, Xu, Zhe, Shi, Fanchao, McEvoy, John William, Herrington, William, Visseren, Frank L J, Wood, Angela, Eliasson, Björn, Sattar, Naveed, Wild, Sarah, Di Angelantonio, Emanuele, Dorresteijn, Jannick A N, Interne Geneeskunde Vasculaire, Circulatory Health, MS Interne Geneeskunde, Østergaard, Helena Bleken, Hageman, Steven H J, Read, Stephanie H, Taylor, Owen, Pennells, Lisa, Kaptoge, Stephen, Petitjean, Carmen, Xu, Zhe, Shi, Fanchao, McEvoy, John William, Herrington, William, Visseren, Frank L J, Wood, Angela, Eliasson, Björn, Sattar, Naveed, Wild, Sarah, Di Angelantonio, Emanuele, and Dorresteijn, Jannick A N

Published
2023

46. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.

Author

Burger, Pascal M, Dorresteijn, Jannick A N, Fiolet, Aernoud T L, Koudstaal, Stefan, Eikelboom, John W, Nidorf, Stefan M, Thompson, Peter L, Cornel, Jan H, Budgeon, Charley A, Westendorp, Iris C D, Beelen, Driek P W, Martens, Fabrice M A C, Steg, Philippe Gabriel, Asselbergs, Folkert W, Cramer, Maarten J, Teraa, Martin, Bhatt, Deepak L, Visseren, Frank L J, Mosterd, Arend, and for the LoDoCo2 Trial Investigators

Published
2023
Full Text
View/download PDF

47. Validation of spot urine in estimating 24-h urinary sodium, potassium and sodium-to-potassium ratio during three different sodium diets in healthy adults.

Author

Groenland, Eline H., Vendeville, Jean-Paul A. C., Bots, Michiel L., Visseren, Frank L. J., Musson, Ruben E. A., and Spiering, Wilko

Subjects
DIETARY sodium, HIGH-salt diet, SALT-free diet, POTASSIUM, SODIUM, THIRST
Abstract

To evaluate the validity of spot urine assay methods in estimating the 24-h urinary sodium, potassium and sodium-to-potassium ratio during three different sodium diets. Twelve healthy volunteers were asked to adhere to 3 dietary sodium targets (3.3–5.0g/day,<3.3 g/day and >5.0 g/day) for three consecutive weeks and to measure salt excretion daily in spot urine samples using a self-monitoring device. On day 7 of each week, 24-h urine was collected to compare measured with estimated 24-h salt excretion (by the Kawasaki, Tanaka and INTERSALT equations). Correlation coefficients relating measured and estimated 24-h sodium excretion were low and not significant for Kawasaki and INTERSALT and moderate for the Tanaka equation (τ 0.56–0.64,p<.05). Bland–Altman plots showed considerable differences between estimated and measured sodium excretion across all salt diets. Over 40% of the participants showed an absolute difference between measured and estimated 24-h sodium of more than 1000 mg/day. The correlation coefficients between 24-h and spot Na/K ratio were 0.67, 0.94 and 0.85(p<.05), and mean differences were 0.59, 0.06 and 0.48 for the intermediate, low and high sodium diets, respectively. These findings do not support estimation of individual 24-h salt excretion from spot urine by the Kawasaki, Tanaka, or INTERSALT formula. Accurate monitoring of salt intake is essential to improve BP control. At present, measurement of sodium and potassium excretion in multiple non-consecutive 24-h urinary collections is considered the gold standard for measuring dietary sodium intake. However, this method is burdensome, time-consuming and error prone. Therefore, we assessed and compared the validity of three formula-based approaches to estimate 24-h urinary sodium and potassium excretion and the Na/K ratio from spot urine samples measured by a self-monitoring device under three different sodium diets using 24-h urine collections as the reference. We conclude that use of three commonly used equations that estimate 24-h urinary sodium and potassium excretion result in substantial bias, poor precision and poor accuracy and are therefore not recommended. The Na/K ratio based on multiple casual urine samples may be a useful, low-burden, low-cost alternative method to 24-h urine collection for monitoring daily salt intake. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease

Author

Hageman, Steven H. J., McKay, Ailsa J., Ueda, Peter, Gunn, Laura H., Jernberg, Tomas, Hagström, Emil, Bhatt, Deepak L., Steg, Ph. Gabriel, Läll, Kristi, Mägi, Reedik, Gynnild, Mari Nordbø, Ellekjær, Hanne, Saltvedt, Ingvild, Tuñón, José, Mahíllo, Ignacio, Aceña, Álvaro, Kaminski, Karol, Chlabicz, Malgorzata, Sawicka, Emilia, Tillman, Taavi, McEvoy, John W., di Angelantonio, Emanuele, Graham, Ian, de Bacquer, Dirk, Ray, Kausik K., Dorresteijn, Jannick A. N., Visseren, Frank L. J., Asselbergs, F. W., Nathoe, H. M., de Borst, G. J., Bots, M. L., Geerlings, M. I., Emmelot, M. H., de Jong, P. A., Leiner, T., Lely, A. T., van der Kaaij, N. P., Kappelle, L. J., Ruigrok, Y. M., Verhaar, M. C., Visseren, F. L. J., Westerink, J., Halle, Martin, Timmis, Adam D., Lettino, Maddalena, Vardas, Panos E., McEvoy, John William, Graham, Ian M., and Academic Medical Center

Subjects
Cardiac & Cardiovascular Systems, PREDICTION, Myocardial Infarction, Residual risk, Risk Assessment, ARTERIAL-DISEASE, Recurrent risk, Risk Factors, Medicine and Health Sciences, Humans, Cardiac and Cardiovascular Systems, 1102 Cardiorespiratory Medicine and Haematology, METAANALYSIS, Science & Technology, Kardiologi, Secondary prevention, 1103 Clinical Sciences, ASSOCIATION, Atherosclerosis, Established ASCVD, COMPETING RISKS, PREVENTION, Risk prediction, Stroke, ASPIRIN, Cardiovascular System & Hematology, Cardiovascular Diseases, CLINICAL-PRACTICE, Personalized treatment, Cardiovascular System & Cardiology, Cardiology and Cardiovascular Medicine, OUTPATIENTS, Life Sciences & Biomedicine, Algorithms, Biomarkers, TASK-FORCE
Abstract

Aims The 10-year risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events in patients with established ASCVD can be estimated with the Secondary Manifestations of ARTerial disease (SMART) risk score, and may help refine clinical management. To broaden generalizability across regions, we updated the existing tool (SMART2 risk score) and recalibrated it with regional incidence rates and assessed its performance in external populations. Methods and results Individuals with coronary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysms were included from the Utrecht Cardiovascular Cohort-SMART cohort [n = 8355; 1706 ASCVD events during a median follow-up of 8.2 years (interquartile range 4.2-12.5)] to derive a 10-year risk prediction model for recurrent ASCVD events (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular mortality) using a Fine and Gray competing risk-adjusted model. The model was recalibrated to four regions across Europe, and to Asia (excluding Japan), Japan, Australia, North America, and Latin America using contemporary cohort data from each target region. External validation used data from seven cohorts [Clinical Practice Research Datalink, SWEDEHEART, the international REduction of Atherothrombosis for Continued Health (REACH) Registry, Estonian Biobank, Spanish Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction (BACS/BAMI), the Norwegian COgnitive Impairment After STroke, and Bialystok PLUS/Polaspire] and included 369 044 individuals with established ASCVD of whom 62 807 experienced an ASCVD event. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] in BACS/BAMI to 0.772 (95% CI 0.659-0.886) in REACH Europe high-risk region. The clinical utility of the model was demonstrated across a range of clinically relevant treatment thresholds for intensified treatment options. Conclusion The SMART2 risk score provides an updated, validated tool for the prediction of recurrent ASCVD events in patients with established ASCVD across European and non-European populations. The use of this tool could allow for a more personalized approach to secondary prevention based upon quantitative rather than qualitative estimates of residual risk. Key objective To improve upon prediction of 10-year residual atherosclerotic cardiovascular disease (ASCVD) event risk in individuals with established ASCVD, by taking into account competing risks and geographical differences in ASCVD incidence. Key findings Derivation in 8355 individuals with established ASCVD from the Utrecht Cardiovascular Cohort-Secondary Manifestations of ARTerial disease (SMART) cohort. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] to 0.772 (95% CI 0.659-0.886). Clinical utility was demonstrated across a range of treatment thresholds relevant to therapy intensification. Take-home messages The SMART2 risk score can be used to estimate 10-year residual risk of fatal and non-fatal ASCVD in individuals with established ASCVD. Adapted to the CVD incidence in several global regions. Facilitates shared decision-making on Step 2 prevention goals as recommended by the 2021 ESC Guidelines on cardiovascular prevention.

Published
2022
Full Text
View/download PDF

50. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

Author

van Trier, Tinka J, primary, Snaterse, Marjolein, additional, Hageman, Steven H J, additional, ter Hoeve, Nienke, additional, Sunamura, Madoka, additional, Moll van Charante, Eric P, additional, Galenkamp, Henrike, additional, Deckers, Jaap W, additional, Martens, Fabrice M A C, additional, Visseren, Frank L J, additional, Scholte op Reimer, Wilma J M, additional, Peters, Ron J G, additional, and Jørstad, Harald T, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results